Andere talen Tourmaline Bio, Inc.

Aandelen

TRML

US89157D1054

Geschatte realtime Cboe BZX Andere beurzen 16:43:35 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
15,52 ^USD	-0,89%		-22,28%	-40,18%

21/03	Wall Street gaat hoger openen nadat de Fed de rente stabiel houdt; eerste werkloosheidsclaims lager dan verwacht	MT
21/03	Amerikaanse futures bewegen hoger na besluit Fed om de rente ongewijzigd te laten	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Wall Street Set to Open Higher After Fed Holds Interest Rates Steady; Initial Jobless Claims Lower Than Expected	21/03
US Futures Trend Higher After Fed Decision to Hold Interest Rates Steady	21/03
Top Premarket Decliners	21/03
Tourmaline Reports Q4 Net Loss; Cash to Fund Operations Until 2027	19/03
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	19/03
Tourmaline Bio, Inc. Plans to Commence a Phase 2 Trial Evaluating Quarterly Subcutaneous Dosing of TOUR006 in Patients with Elevated Cardiovascular Risk in the First Half of 2024	19/03
Tourmaline Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Tourmaline Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Tourmaline Bio Insider Bought Shares Worth $3,250,000, According to a Recent SEC Filing	31/01
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	29/01
Tourmaline Bio Prices $150 Million Common Stock Offering	25/01
Tourmaline Bio Announces Pricing of Public Offering of Common Stock	25/01
Tourmaline Bio Announces Proposed Public Offering of Common Stock	24/01
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)	08/01
Tourmaline Bio, Inc.(NasdaqGS:TRML) added to NASDAQ Biotechnology Index	18/12
Tourmaline Bio Joins Nasdaq Biotechnology Index	15/12
Tourmaline Bio added to the NASDAQ Biotechnology Index	15/12
Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director	14/12
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board	14/12
Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors	30/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Tourmaline Bio, Inc.

Aandelen

TRML

US89157D1054

Andere talen

Filters